中华妇产科杂志
中華婦產科雜誌
중화부산과잡지
CHINESE JOUNAL OF OBSTETRICS AND GYNECOLOGY
2010年
11期
808-812
,共5页
储萍%路春华%盛修贵%周彩霞%李大鹏%杜雪莲%刘乃富
儲萍%路春華%盛脩貴%週綵霞%李大鵬%杜雪蓮%劉迺富
저평%로춘화%성수귀%주채하%리대붕%두설련%류내부
抗肿瘤联合化疗方案%异环磷酰胺%卵巢肿瘤%肿瘤复发,局部%吉西他滨
抗腫瘤聯閤化療方案%異環燐酰胺%卵巢腫瘤%腫瘤複髮,跼部%吉西他濱
항종류연합화료방안%이배린선알%란소종류%종류복발,국부%길서타빈
Antineoplastic combined chemotherapy protocols%Ifosfamide%Ovarian neoplasms%Neoplasm recurrence,local%Gemcitabine
目的 评价以吉西他滨为基础联合异环磷酰胺和蒽环类药物治疗复发性铂类耐药卵巢上皮性癌(卵巢癌)的近期疗效及毒副反应.方法 对60例复发性铂类耐药卵巢癌患者应用吉西他滨、异环磷酰胺和蒽环类药物联合化疗方案[吉西他滨800 mg/m2,第1、8天;异环磷酰胺1.5 g/m2,第1～3天;多柔比星(其他名称:阿霉素)40 mg/m2或表柔比星(其他名称:表阿霉素)60 mg/m2(第1天),或米托蒽醌10 mg/m2(第1、8天);21～28 d重复],回顾性分析其临床病理资料.结果 60例患者共接受172个疗程的化疗.完全缓解0例,部分缓解22例(37%,22/60),稳定23例(38%,23/60),疾病进展15例(25%,15/60),临床总获益率75%(45/60);中位无疾病进展生存期为7个月,中位总生存期为20个月.主要不良反应为骨髓抑制,白细胞减少发生率达82%(49/60),其中Ⅲ～Ⅳ度占31%(15/49);消化道反应均为Ⅰ、Ⅱ度,占42%(25/60).结论 以吉西他滨为基础的联合化疗可作为铂类耐药的复发性卵巢癌的治疗方案之一,毒副反应可以耐受.
目的 評價以吉西他濱為基礎聯閤異環燐酰胺和蒽環類藥物治療複髮性鉑類耐藥卵巢上皮性癌(卵巢癌)的近期療效及毒副反應.方法 對60例複髮性鉑類耐藥卵巢癌患者應用吉西他濱、異環燐酰胺和蒽環類藥物聯閤化療方案[吉西他濱800 mg/m2,第1、8天;異環燐酰胺1.5 g/m2,第1～3天;多柔比星(其他名稱:阿黴素)40 mg/m2或錶柔比星(其他名稱:錶阿黴素)60 mg/m2(第1天),或米託蒽醌10 mg/m2(第1、8天);21～28 d重複],迴顧性分析其臨床病理資料.結果 60例患者共接受172箇療程的化療.完全緩解0例,部分緩解22例(37%,22/60),穩定23例(38%,23/60),疾病進展15例(25%,15/60),臨床總穫益率75%(45/60);中位無疾病進展生存期為7箇月,中位總生存期為20箇月.主要不良反應為骨髓抑製,白細胞減少髮生率達82%(49/60),其中Ⅲ～Ⅳ度佔31%(15/49);消化道反應均為Ⅰ、Ⅱ度,佔42%(25/60).結論 以吉西他濱為基礎的聯閤化療可作為鉑類耐藥的複髮性卵巢癌的治療方案之一,毒副反應可以耐受.
목적 평개이길서타빈위기출연합이배린선알화은배류약물치료복발성박류내약란소상피성암(란소암)적근기료효급독부반응.방법 대60례복발성박류내약란소암환자응용길서타빈、이배린선알화은배류약물연합화료방안[길서타빈800 mg/m2,제1、8천;이배린선알1.5 g/m2,제1～3천;다유비성(기타명칭:아매소)40 mg/m2혹표유비성(기타명칭:표아매소)60 mg/m2(제1천),혹미탁은곤10 mg/m2(제1、8천);21～28 d중복],회고성분석기림상병리자료.결과 60례환자공접수172개료정적화료.완전완해0례,부분완해22례(37%,22/60),은정23례(38%,23/60),질병진전15례(25%,15/60),림상총획익솔75%(45/60);중위무질병진전생존기위7개월,중위총생존기위20개월.주요불량반응위골수억제,백세포감소발생솔체82%(49/60),기중Ⅲ～Ⅳ도점31%(15/49);소화도반응균위Ⅰ、Ⅱ도,점42%(25/60).결론 이길서타빈위기출적연합화료가작위박류내약적복발성란소암적치료방안지일,독부반응가이내수.
Objective To evaluate the efficacy and toxicities of gemcitabine combined with ifosfamide and anthracycline chemotherapy for recurrent platinum resistant ovarian epithelial cancer.Methods Gemcitabine 800 mg/m2 ( day 1, 8 ), ifosfamide 1.5 g/m2 ( day 1 - 3 ), adriamycin 40 mg/m2 or epirubicin 60 mg/m2 (day 1 ) or mitoxantrone 10 mg/m2 (day 1, 8 ) were used in recurrent platinum resistant/refractory ovarian cancer patients, the cycle was repeated at interval of 21 to 28 days.Results A total of 60 patients received 172 cycles combined chemotherapy.There were no one cases complete response, while partial response 22 (37%, 22/60), stable 23 (38%, 23/60) and progression 15 (25%,15/60) were observed, with clinical benefit rate 75% (45/60).The median time of progression-free survival was 7 months, and the median overall survival time was 20 months.The main side effect was hematologic toxicity with leukopenia rate of 82% (49/60), among which Ⅲ - Ⅳ accounted for 31%(15/49).Digestive reaction was all in Ⅰ - Ⅱ , accounted for 42% (25/60).Conclusion The regimen of gemcitabine combined with ifosfamide and anthracycline is feasible, tolerable and effective in patients with recurrent platinum resistant/refractory epithelial ovarian cancer.
